H
Ho Jin Shin
Researcher at Pusan National University
Publications - 124
Citations - 2029
Ho Jin Shin is an academic researcher from Pusan National University. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 21, co-authored 103 publications receiving 1709 citations. Previous affiliations of Ho Jin Shin include New Generation University College.
Papers
More filters
Journal ArticleDOI
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer,Suzanne Lentzsch,Katja Weisel,Hervé Avet-Loiseau,Tomer M Mark,Ivan Spicka,Tamás Masszi,Birgitta Lauri,Mark-David Levin,Alberto Bosi,Vania Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Cindy Lee,Wolney Barreto,Paolo Corradini,Chang-Ki Min,Emma C. Scott,Asher Chanan-Khan,Noemi Horvath,Marcelo Capra,Meral Beksac,Roberto Ovilla,Jae Cheol Jo,Ho Jin Shin,Pieter Sonneveld,David Soong,Tineke Casneuf,Christopher Chiu,Himal Amin,Ming Qi,Piruntha Thiyagarajah,A. Kate Sasser,Jordan M. Schecter,Maria-Victoria Mateos +36 more
TL;DR: Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse.
Journal ArticleDOI
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Dong Hwan Kim,Hee Du Jung,Jong Gwang Kim,Je-Jung Lee,Deok-Hwan Yang,Yeon Hee Park,Young Rok Do,Ho Jin Shin,Min Kyoung Kim,Myung Soo Hyun,Sang Kyun Sohn +10 more
TL;DR: The FCGR3A single nucleotide polymorphism (SNP) is predictive of response to R-CHOP, but does not correlate with survival in patients with DLBCL, and FcR polymorphism can affect rituximab's affinity for ADCC effector cells.
Journal ArticleDOI
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Jong Gwang Kim,Sang Kyun Sohn,Yee Soo Chae,Yoon Young Cho,Deok Hwan Yang,Je-Jung Lee,Hyeoung-Joon Kim,Ho Jin Shin,Joo Seop Chung,Goon Jae Cho,Won-Sik Lee,Young-Don Joo,Chang-Hak Sohn,Sukjoong Oh +13 more
TL;DR: The alemtuzumab plus CHOP chemotherapy seemed to produce active antitumor activity in terms of the complete response rates in patients with PTCLs, but since high infectious and hematologic toxicities were observed, careful monitoring and early treatment are needed to prevent treatment-related mortality.
Journal ArticleDOI
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study
Seok Jin Kim,Jong Wook Lee,Chul Won Jung,Chang-Ki Min,Cho Bs,Ho Jin Shin,Joo Seop Chung,Hawk Kim,Won Sik Lee,Young Don Joo,Deok Hwan Yang,Hoon Kook,Hyoung Jin Kang,Hyo Seop Ahn,Sung-Soo Yoon,Sang Kyun Sohn,Yoo Hong Min,Woo Sung Min,Hee Sook Park,Jong Ho Won +19 more
TL;DR: Rituximab could improve clinical responses and quality of life of patients with steroid-refractory chronic graft-versus-host disease, although such patients may need active prophylaxis against infection.
Journal ArticleDOI
Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy
Young Mi Seol,Bo Ran Kwon,Moo Kon Song,Youngjin Choi,Ho Jin Shin,Joo Seop Chung,Goon Jae Cho,Jin Chun Lee,Byung Joo Lee,Soo Geun Wang,Hak-Jin Kim,Won Taek Kim,Seung Jang Kim,Eun Young Yun +13 more
TL;DR: Quantitative measurement of tumor volume separates patients with a good prognosis from those with a poorer prognosis, and a subset of patients with relatively small tumors and no lymph node involvement did very well.